Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

Kalil, André C.; Patterson, Thomas F.; Mehta, Aneesh K.; Tomashek, Kay M; Wolfe, Cameron R.; Ghazaryan, Varduhi; Marconi, Vincent C.; Ruiz‐Palacios, Guillermo M.; Hsieh, Lanny; Kline, Susan; Tapson, Victor F.; Iovine, Nicole M.; Jain, Mamta K.; Sweeney, Daniel A; Sahly, Hana M. El; Branche, Angela R; Pineda, Justino Regalado; Lye, David Chien; Sandkovsky, Uriel; Luetkemeyer, Anne F.; Cohen, Stuart H.; Finberg, Robert W.; Jackson, Patrick; Taiwo, Babafemi; Paules, Catharine I.; Arguinchona, Henry; Erdmann, Nathaniel; Ahuja, Neera; Frank, Maria G.; Oh, Myoung‐don; Kim, Eu Suk; Tan, Seow Yen; Mularski, Richard A.; Nielsen, Henrik; Ponce, Philip O.; Taylor, Barbara S.; Larson, LuAnn; Rouphael, Nadine; Saklawi, Youssef; Cantos, Valeria D; Ko, Emily R.; Engemann, John J.; Amin, Alpesh; Watanabe, Miki; Billings, Joanne; Elie, Marie‐Carmelle; Davey, Richard T.; Burgess, Timothy; Ferreira, Jennifer; Green, Michelle; Makowski, Mat; Cardoso, Anabela; Bono, Stephanie de; Bonnett, Tyler; Proschan, Michael A.; Deye, Gregory A.; Dempsey, Walla; Nayak, Seema; Dodd, Lori E.; Beigel, John H.

doi:10.1056/nejmoa2031994

articleNew England Journal of MedicineDec 11, 2020GREEN OA

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

ACAndré C. Kalil TFThomas F. Patterson AKAneesh K. Mehta KMKay M Tomashek CRCameron R. Wolfe

The University of Texas Health Science Center at San Antonio · Texas A&M University System · +1 more institution

PubMed

Indexed incrossrefpubmed

Abstract

Background

Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.

Methods

We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15.

Citation impact

1,910

total citations

FWCI: 40.85
Percentile: 100%
References: 21

Citations per year

Authors

60

Topics & keywords

Topics

Keywords

Coronavirus disease 2019 (COVID-19)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
2019-20 coronavirus outbreak
Medicine
Virology
Betacoronavirus
Internal medicine
Infectious disease (medical specialty)

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.